


## **Transcenta partners with BMS**

22 March 2022 | News

Transcenta announces global clinical collaboration with Bristol Myers Squibb to evaluate TST001 in combination with Opdivo in patients with locally advanced or metastatic gastric / gastroesophageal junction cancer



Transcenta Holding Limited, a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has established a global clinical collaboration with Bristol Myers Squibb to evaluate the combination of TST001, an investigational humanized monoclonal antibody targeting Claudin18.2 developed by Transcenta, with Opdivo (nivolumab), Bristol Myers Squibb's anti-PD-1 therapy, for the treatment of patients with unresectable locally advanced or metastatic gastric cancer or gastroesophageal junction cancer (GC/GEJ).

This collaboration includes two global phase I/II open-label, multi-center studies, one to be held in the U.S. and one to be held in China, to evaluate the safety, tolerability, and anti-tumor efficacy of TST001 in combination with *Opdivo* in patients with unresectable locally advanced or metastatic Claudin18.2 expressing gastric / gastroesophageal junction cancer with or without previous treatment.

Under the terms of the agreement, Transcenta will be the sponsor of the trials and Bristol Myers Squibb will supply *Opdivo* to Transcenta for use in its combination therapy studies with TST001.